Skip to Main content Skip to Navigation
Journal articles

Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer

Abstract : Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women, and there has been no substantial decrease in the death rates due to EOC in the last three decades. Thus, basic knowledge regarding ovarian tumor cell biology is urgently needed to allow the development of innovative treatments for EOC. Traditionally, EOC has not been considered an immunogenic tumor, but there is evidence of an immune response to EOC in patients. Clinical data demonstrate that an antitumor immune response and immune evasion mechanisms are correlated with a better and lower survival, respectively, providing evidence for the immunoediting hypothesis in EOC. This review focuses on the immune response and immune suppression in EOC. The immunological roles of chemotherapy and surgery in EOC are also described. Finally, we detail pilot data supporting the efficiency of immunotherapy in the treatment of EOC and the emerging concept that immunomodulation aimed at counteracting the immunosuppressive microenvironment must be associated with immunotherapy strategies.
Document type :
Journal articles
Complete list of metadata

Cited literature [158 references]  Display  Hide  Download
Contributor : Ed. BMC Connect in order to contact the contributor
Submitted on : Saturday, June 15, 2013 - 1:02:53 AM
Last modification on : Wednesday, March 30, 2022 - 2:34:45 PM
Long-term archiving on: : Monday, September 16, 2013 - 2:30:10 AM




Vincent Lavoué, Aurélie Thédrez, Jean Levêque, Fabrice Foucher, Sébastien Henno, et al.. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. Journal of Translational Medicine, BioMed Central, 2013, 11 (1), pp.147. ⟨10.1186/1479-5876-11-147⟩. ⟨inserm-00834422⟩



Record views


Files downloads